• Envoy Medical submitted the second module of its rolling PMA to the FDA for the breakthrough-designated Acclaim cochlear implant.
• The engineering-focused filing advances FDA review ahead of the final clinical module, which Envoy targets for submission in Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610120830NEWSFILECNPR____20261012_318503_1) on October 12, 2026, and is solely responsible for the information contained therein.